Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NWBO Northwest Biotherapeutics Inc
- Stocks
- Healthcare
- OTC: NWBO
Price (delayed)
$0.2275
Market cap
$327.07M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.07
Enterprise value
$393.3M
Highlights
Northwest Biotherapeutics's revenue has increased by 10% YoY and by 7% QoQ
The company's gross profit rose by 10% YoY and by 7% QoQ
NWBO's debt is up by 41% YoY and by 2.3% QoQ
The equity has contracted by 36% YoY and by 5% from the previous quarter
Key stats
What are the main financial stats of NWBO
Market
Valuations
Earnings
Shares outstanding
1.44B
Market cap
$327.07M
Enterprise value
$393.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
209.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
267.01
Revenue
$1.47M
Gross profit
$1.47M
Operating income
-$68.08M
Net income
-$84.81M
EBIT
-$76.96M
EBITDA
-$74.92M
Free cash flow
-$54.9M
Per share
Balance sheet
Liquidity
EPS
-$0.07
EPS diluted
-$0.07
Free cash flow per share
-$0.04
Book value per share
-$0.07
Revenue per share
$0
TBVPS
$0.02
Total assets
$27.51M
Total liabilities
$112.34M
Debt
$69.01M
Equity
-$99.48M
Working capital
-$78.37M
Debt to equity
-0.69
Current ratio
0.06
Quick ratio
0.03
Net debt/EBITDA
-0.88
Margins
Efficiency
Dividend
EBITDA margin
-5,086.3%
Gross margin
100%
Net margin
-5,757.6%
Operating margin
-4,621.5%
Return on assets
-307.5%
Return on equity
N/A
Return on invested capital
-401.8%
Return on capital employed
N/A
Return on sales
-5,224.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NWBO stock price
How has the Northwest Biotherapeutics stock price performed over time
Intraday
2.02%
1 week
-8.45%
1 month
-13.17%
1 year
-42.3%
YTD
-17.21%
QTD
-5.17%
Financial performance
How have Northwest Biotherapeutics's revenue and profit performed over time
Revenue
$1.47M
Gross profit
$1.47M
Operating income
-$68.08M
Net income
-$84.81M
Gross margin
100%
Net margin
-5,757.6%
NWBO's net income is down by 21% year-on-year
NWBO's operating income is down by 17% YoY and by 2.4% from the previous quarter
Northwest Biotherapeutics's revenue has increased by 10% YoY and by 7% QoQ
The company's gross profit rose by 10% YoY and by 7% QoQ
Price vs fundamentals
How does NWBO's price correlate with its fundamentals
Growth
What is Northwest Biotherapeutics's growth rate over time
Valuation
What is Northwest Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
209.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
267.01
The EPS has contracted by 17% YoY
The equity has contracted by 36% YoY and by 5% from the previous quarter
The P/S is 60% below the 5-year quarterly average of 528.0 and 18% below the last 4 quarters average of 255.8
Northwest Biotherapeutics's revenue has increased by 10% YoY and by 7% QoQ
Efficiency
How efficient is Northwest Biotherapeutics business performance
The return on assets has declined by 24% year-on-year
The ROS has contracted by 8% YoY but it has grown by 5% from the previous quarter
The ROIC has decreased by 4% QoQ but it has increased by 2.5% YoY
Dividends
What is NWBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NWBO.
Financial health
How did Northwest Biotherapeutics financials performed over time
The total assets is 76% smaller than the total liabilities
NWBO's total liabilities is up by 37% year-on-year and by 6% since the previous quarter
Northwest Biotherapeutics's quick ratio has decreased by 25% YoY
NWBO's debt is 169% higher than its equity
NWBO's debt is up by 41% YoY and by 2.3% QoQ
The equity has contracted by 36% YoY and by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.